ABCC6 Deficiency – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 

The ATP-binding cassette (ABC) transporters represent an extensive family of membrane efflux transporters comprising 48 distinct members. These transporters exhibit diverse substrate specificities, including lipids, peptides, polysaccharides, organic molecules, and ions. Phylogenetic analysis reveals that ABCC6 shares the highest sequence homology with ABCC1 and ABCC2, which are recognized as multidrug resistance transporters and are known to transport a variety of substrates relevant to clinically significant pharmaceutical agents. The endogenous substrate for ABCC6 remains unidentified. Mutations in ABCC6 are the genetic basis for the rare disorder pseudoxanthoma elasticum (PXE). PXE is an autosomal recessive condition characterized by ectopic mineralization of the skin, retina, and arteries, leading to skin papules, blindness, and arterial sclerosis. Histologically, PXE is defined by the calcification of elastic fibers. Infants with ABCC6 deficiency may present with Generalized Arterial Calcification (GACI) Type 2, which resembles GACI Type 1, the infantile form of ENPP1 deficiency. In older individuals, ABCC6 deficiency manifests as PXE, characterized by pathological mineralization in blood vessels and soft tissues, clinically impacting the skin, eyes, and vascular system.

Thelansis’s “ABCC6 Deficiency Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential ABCC6 Deficiency treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of ABCC6 Deficiency across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

ABCC6 Deficiency Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: ABCC6 Deficiency – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033